威利斯金融租賃 WLFC 深 滬
交易中 09-10 11:03:36 美东时间
149.18
+2.010
+1.37%
華盛通- 最 高151.025
- 今 開147.43
- 成交量 6975股
- 最 低 147.43
- 昨 收 147.17
- 總市值 10.30亿
- 52周最高 234.425
- 市盈率 靜 9.72
- 換手率 0.10%
- 52周最低 124.40
- 委 比 8.33%
- 總股本 690.30万
- 歷史最高 234.425
- 量 比 0.94
- 振 幅 2.44%
- 歷史最低 7.66
- 每 手 1
- 風險率 29.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Willis launches new Global Risk Engineering team to enhance global specialization
Willis, a WTW business, has launched its new Global Risk Engineering team, a key expansion of its Global Risk & Analytics business. This team consolidates and elevates engineering capabilities, enabling industry-leading specialization through proprietary data, advanced analytics, and technology. With nearly 200 risk engineers across 30 countries, the team provides single-site and portfolio-level assessments to enhance client insights, resilience,...
09-09 08:14
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
Werewolf Therapeutics, Inc., a biopharmaceutical company, announced that its President and CEO, Daniel J. Hicklin, Ph.D., and Chief Medical Officer, Randi Isaacs, M.D., will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. The event will be webcast live with an archive available for 90 days. The company specializes in developing immune-stimulating therapeutics for cancer and immu...
09-02 12:00
TeraWulf Inc. Announces Full Exercise of Greenshoe Option in $1.0 Billion Convertible Senior Notes Offering
TeraWulf Inc. has announced the full exercise of an option by the initial purchasers of its 1.00% Convertible Senior Notes due 2031, resulting in an additional $150 million aggregate principal amount of notes being purchased. Including the greenshoe, the total principal amount of Convertible Notes sold in the offering reached $1.0 billion. The offering was conducted as a private placement under Rule 144A. In connection with the additional note...
08-22 20:05
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics provides updates on its clinical trials, including interim data readouts for WTX-124 in late 2025 and plans to engage with FDA for registrational pathways. WTX-330's Phase 1b/2 trial is enrolling, with dosing regimen to be determined by year-end. The company introduces WTX-1011, its first INDUCER T-cell engager targeting STEAP1 for prostate cancer, showcasing promising preclinical data. Financially, the company has $77.6 mil...
08-14 11:00
Willis Lease Finance Q2 Adj. EPS $3.43 Beats $3.18 Estimate, Sales $195.502M Beat $143.000M Estimate
Willis Lease Finance (NASDAQ:WLFC) reported quarterly earnings of $3.43 per share which beat the analyst consensus estimate of $3.18 by 7.86 percent. This is a 44.77 percent decrease over earnings of $6.21 per share from
08-05 18:34
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Willis Lease Finance Declares Quarterly Dividend
Willis Lease Finance ( ($WLFC) ) has provided an update. On July 30, 2025, Will...
07-31 22:47
Willis Lease Finance declares $0.25 dividend
Willis Lease Finance (NASDAQ:WLFC) declares $0.25/share quarterly dividend, in line with previous. Forward yield 0.71% Payable Aug. 21; for shareholders of record Aug. 12; ex-div Aug. 12. See WLFC Div...
07-31 22:17
Willis Lease Finance Amends Credit Agreement Terms
Willis Lease Finance ( ($WLFC) ) has issued an update. On July 22, 2025, Willis...
07-25 22:57
Willis Lease Finance Corporation Announces Timing of Second Quarter 2025 Financial Results and Conference Call
Willis Lease Finance Corporation announces the release of its Q2 2025 financial results on August 5, 2025, before market open. A conference call will be held at 10:00 a.m. ET the same day. Participants can join via U.S./Canada: +1 (800) 289-0459 or International: +1 (646) 828-8082 with Conference ID 101023. A digital replay will be available on the company's website under Investor Relations.
07-15 12:01
